Analyst Ami Fadia of Needham maintained a Buy rating on Immuneering (IMRX – Research Report), with a price target of $9.00.
Ami Fadia has given his Buy rating due to a combination of factors including Immuneering’s recent earnings report and future plans. The company reported an EPS of -$0.42 for the first quarter of 2025, which was in line with market expectations. A key highlight from the earnings report was the anticipated disclosure of initial progression-free survival data from over 30 patients in a first-line pancreatic ductal adenocarcinoma study for their drug IMM-1-104, expected in the second quarter of 2025. This data could potentially validate the promising efficacy observed in earlier phase 2A trials.
Additionally, Immuneering’s management has outlined plans for a phase 3 study of IMM-1-104 in combination with mGnP for first-line pancreatic cancer, scheduled for 2026. These strategic developments, along with the company’s ongoing efforts to advance their pipeline, contribute to the positive outlook and justify the Buy rating. The forward-looking plans and upcoming data releases are seen as significant catalysts for the stock, supporting the investment recommendation.